New eczema pill shows promise in early safety trial
NCT ID NCT06345404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and tolerability, while also looking for signs of symptom improvement. Participants received either the drug or a placebo, and researchers monitored side effects and changes in eczema severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
soquelitinib (also known as CPI-818)
What this could lead to
If it works, this could point toward a new oral treatment option for people with moderate to severe eczema that is not controlled by current therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The small size and lack of long-term data mean it may not lead to a viable treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
Camp Hill, Pennsylvania, 17011, United States
-
Clinical Site 10
Castle Rock, Colorado, 80109, United States
-
Clinical Site 11
Brooklyn, New York, 11203, United States
-
Clinical Site 12
New York, New York, 10075, United States
-
Clinical Site 13
Pomona, California, 91767, United States
-
Clinical Site 14
San Antonio, Texas, 78213, United States
-
Clinical Site 15
Mayfield Heights, Ohio, 44124, United States
-
Clinical Site 16
New York, New York, 10023, United States
-
Clinical Site 2
Fremont, California, 94538, United States
-
Clinical Site 3
North Little Rock, Arkansas, 72117, United States
-
Clinical Site 4
Frisco, Texas, 75034, United States
-
Clinical Site 5
Birmingham, Alabama, 35244, United States
-
Clinical Site 6
Tampa, Florida, 33615, United States
-
Clinical Site 7
Palo Alto, California, 94063, United States
-
Clinical Site 8
Philadelphia, Pennsylvania, 19103, United States
-
Clinical Site 9
Tucson, Arizona, 85704, United States